INTRODUCTION

CAUSATIVE AGENT OF LASSA FEVER
Lassa fever is caused by the Lassa virus, a member of the arena viridae; it is an enveloped, single-stranded, bisegmented RNA virus (3).
The virions exhibit pleomorphic morphology when examined by cryoelectron microscopy.
The surface of the virion envelope is studded with glycoprotein projections that consist of tetrameric complexes of the viral Glycoprotein GP1 and GP2 (6) .
The genome of Lassa virus like other arena consists of two single-stranded RNA segments designated S (small) and L (large). In virions, the molar ratio of S to L RNAs is roughly 2:1. The 5' terminus of each segment contains a tri-or diphosphate group and lacks a cap structure. The S RNA segment contains two genes that encode three final gene products-the nucleo protein (NP or N) and the envelope glycol proteins GP1 and GP2 (also termed GP-1 and GP-2, or G1 and G2).
GP1 and GP2 are first expressed as a precursor protein, GPC (or GP-C), which is cleaved post translationally (7). The L RNA segment contains two genes that encode two genes product, the viral polymerase (L protein) and Z protein, a small protein of undetermined function (7 ). On both segment, the genes are arranged in an ambisense orientation. The NP and polymerase genes reside at the 3' end of the S and L RNA segment, respectively, and are encoded in the conventional negative sense-that is, they are expressed through transcription of genomecomplimentary mRNAs.
The genes located at the 5' end of the S and L RNA segment, GPC and Z, respectively, are encoded in mRNA sense but there is no evidence that they are translated directly from genomic RNA. These genes are expressed instead through transcription genomic-sense mRNAs from antigenomes, full length complimentary copies of genomic RNAs that function as replicative intermediates (6) . Lassa virus will infect almost every tissue in the human body. It starts with the mucosa, intestine, lungs, and urinary system, and then progresses to the vascular system (4). 
PREVALENCE/INCIDENCE
Dissemination of the infection can be assessed by prevalence of antibodies to the virus in populations. The prevalence of antibodies to the virus is 8-52% 9 in Sierra Leone, 4-55% in Guinea (12) , and in Nigeria (13) . Seropositivity has also been found in the Central African Republic Democratic of the Congo, Mali and Senegal (14) . Sporadic cases have occurred in travellers returning to Britain, the Netherlands, and Germany from the endemic areas.
MORBIDITY AND MORTALITY
Lassa fever affects people of all ages. The disease is mild or has no observable symptoms in about 
LABORATORY DIAGNOSIS
There are a range of laboratory investigations that are performed to diagnose the disease and assess its course and complications. Lassa virus is easily isolated from the blood or serum during the febrile phase of the disease up to 14 or more days after onset, even after the appearance of IFA antibody. Virus can also be detected in necropsy tissues (33, 24) . Other effects of illness include lymphocytopenia and a moderate thrombocytopenia, which are maximal 10-11 days after the onset of symptoms (19) the thrombocytopenia is associated with a serum inhibitor and with the occurrence of haemorrhage, depression of platelet aggregation, and the severity of Lassa fever (19) .
TREATMENT
All persons suspected of Lassa fever infection
should be admitted to isolation facilities and their body fluids and excrete properly disposed. Intravenous interferon therapy has also been used in the management of Lassa fever infection (4).
ANTIVIRAL DRUGS
SUPPORTIVE THERAPY
Supportive therapy is important in the management of patient with lassa fever (43, 44) . The disease also has the potential of being used as biological weapon. It therefore constitutes an infectious menace that must be curbed.
